Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

341

Participants

Timeline

Start Date

October 18, 2013

Primary Completion Date

December 17, 2017

Study Completion Date

March 12, 2018

Conditions
Neuroendocrine TumorsVon Hippel-Lindau SyndromeHippel-Lindau Disease
Interventions
DRUG

68Gallium DOTATATE

Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.

PROCEDURE

Radio-guided surgery

Using 68Gallium DOTATATE

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01967537 - Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter